Regeneus Limited (ASX:RGS) has been granted an Australian patent on stem cell secretions technology as a topical acne treatment.
The regenerative medicine company says the secretions technology utilizes the molecules that are secreted by specific stem cells.
The company says there’s been little innovation in acne treatment over the last ten years and views the global market for acne treatments as sitting at over $3 billion per annum.
Chief Scientific Officer Graham Vesey says a number of the company’s patents are in the final stages of being granted in Australia and are progressing through the overseas examination progress.
Regeneus reported a net loss of $7.5 million in the 2014 financial year.